Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,012.82
-1.77 (-0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,071,801
Open
1,015.40
Bid (Size)
1,012.37 (5)
Ask (Size)
1,012.61 (1)
Prev. Close
1,014.59
Today's Range
1,007.28 - 1,023.09
52wk Range
769.19 - 1,211.20
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Should You Buy the Dip on This Top Growth Stock?
Today 6:30 EDT
The biotech needs to overcome an issue most drugmakers face at some point.
Via
The Motley Fool
A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
October 04, 2024
Via
Benzinga
Performance
YTD
+11.91%
+11.91%
1 Month
-14.12%
-14.12%
3 Month
-2.07%
-2.07%
6 Month
+7.44%
+7.44%
1 Year
+21.86%
+21.86%
More News
Read More
Market Whales and Their Recent Bets on REGN Options
October 03, 2024
Via
Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
October 03, 2024
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
September 30, 2024
Via
Benzinga
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
September 29, 2024
Via
Benzinga
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
September 25, 2024
Via
Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
September 25, 2024
Via
Benzinga
Smart Money Is Betting Big In REGN Options
September 23, 2024
Via
Benzinga
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
September 27, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
September 27, 2024
Via
Benzinga
Exposures
Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
September 27, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
September 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
September 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
September 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
September 26, 2024
Via
Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
September 24, 2024
Via
Benzinga
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
September 24, 2024
Via
Benzinga
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
September 23, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
September 23, 2024
Via
Investor's Business Daily
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
September 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
Via
MarketBeat
Topics
ETFs
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.